SAVE THE DATE: "Mogliano Veneto Seminar" - Edition 7 - Mogliano Veneto, September 26th and 27th 2024

Seminar on early access in oncology

In oncology, especially in the case of pathologies with limited therapeutic alternatives, drugs are increasingly approved on the basis of potentially relevant but early evidence, with limited long-term efficacy and tolerability data. In the countries of the European Union, access to these medicines in the period between the publication of the evidence (phase 2/3), the approval by the EMA and the completion of the reimbursement process is today a serious and complex problem which unfortunately creates significant inequalities from country to country.